Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

A Study of Full-Spectrum Screen Lighting for Reducing Screen-Related Eye Fatigue and Dry Eye

NCT07706231 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2026-09-22
Last updated
2026-09-18

Condition(s) studied

Visual FatigueDry EyeComputer Vision Syndrome

Investigational drug(s) / intervention(s)

Full-spectrum screen bar lightBrightness-matched screen task without screen bar lighting

Full-spectrum screen bar light: The full-spectrum screen bar light will be used as task lighting during an approximately 2-hour standardized screen task in a controlled laboratory environment. Participants will complete computer-based text processing, screen reading, or viewing of specified video materials to simulate prolonged near-screen use.

Brightness-matched screen task without screen bar lighting: Participants will complete the standardized screen task without using a screen bar light. Screen brightness will be adjusted to match the brightness condition of the full-spectrum screen bar lighting arm. The task type, content, duration, and completion requirements will be the same as those in the experimental arm.

Study summary

This study will evaluate whether full-spectrum screen bar lighting can reduce eye fatigue and dry eye symptoms after a standardized screen task. Prolonged screen use is common in daily work and study and may cause blurred vision, eye soreness, dryness, headache, and reduced attention. Light environment may be one way to improve visual comfort during screen use, but more controlled clinical evidence is needed.

In this randomized, parallel-group controlled study, 112 healthy adult participants will be assigned to either a full-spectrum screen bar lighting group or a brightness-matched control group without screen bar lighting. Participants in both groups will complete an approximately 2-hour standardized screen task in a controlled laboratory environment. The study will compare changes before and after the task in objective and subjective measures of visual fatigue and dry eye, including critical flicker fusion frequency, visual fatigue questionnaire scores, eye movement and blinking parameters, pupil parameters, tear film-related measurements, and dry eye symptom scores. Safety and discomfort during the study will also be recorded.

Eligibility

Sex
ALL
Min age
18 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age 18 to 35 years, male or female. 2. Average daily electronic screen exposure of at least 4 hours. 3. Near visual acuity at 40 cm of 0.5 or better, and able to complete the study 1. tasks and measurements stably. 4. Able and willing to provide written informed consent. Exclusion Criteria: 1. Presence of ocular inflammation or ocular disease. 2. History of severe systemic disease, neurological disease, or psychiatric disorder. 3. Use of dry eye or visual fatigue treatments, or contact lens wear, within 1 month before the study. 4. History of ocular surgery within the past 6 months. 5. Daily use of lenses with blue-light blocking, photochromic, polarized, filtering, or similar optical functions. 6. Professional background in ophthalmology or optical products. 7. Intake of caffeine or other stimulants within 4 hours before the study. 8. Best-corrected visual acuity (BCVA) less than 0.8. 9. Anisometropia of 1.00 diopter or greater, or astigmatism of ±2.00 diopters or greater. 10. Intraocular pressure (IOP) less than 5 mmHg or greater than 21 mmHg. 11. Non-invasive tear breakup time (NIBUT) less than 5 seconds in either eye. 12. Ocular Surface Disease Index (OSDI) score of 33 or greater.

Primary outcome measure(s)

  • Change in Critical Flicker Fusion Frequency — Baseline and immediately after completion of the approximately 2-hour standardized screen task
    Critical flicker fusion frequency (CFF) will be measured in Hz using the Handy Flicker HF-III device. The outcome will be calculated as the post-task CFF value minus the baseline CFF value. This measure will be used as an objective indicator of visual fatigue after the standardized screen task.

Trial sites (1)

FacilityCityRegionStatus
Zhongshan Ophthalmic Center Guangzhou Guangdong
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07706231 on ClinicalTrials.gov ↗ ← All trials in China